Harmony Biosciences Holdings (HRMY) Other Accumulated Expenses (2019 - 2026)

Harmony Biosciences Holdings has disclosed Other Accumulated Expenses across 8 years of filings, most recently posting $1.9 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $1.9 million, down 90.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (down 90.52% YoY), and the FY2025 annual result was $5.0 million, up 283.97% from the prior year.
• Other Accumulated Expenses came in at $1.9 million for Q1 2026 at Harmony Biosciences Holdings, down from $5.0 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $25.1 million in Q1 2024 to a low of $773000.0 in Q4 2022.
• The 5-year median for Other Accumulated Expenses is $3.3 million (2022), against an average of $5.9 million.
• Across the five-year window, Other Accumulated Expenses surged 1260.05% in 2024 and plunged 90.52% in 2026, its largest moves.
• Harmony Biosciences Holdings' Other Accumulated Expenses stood at $773000.0 in 2022, then jumped by 910.35% to $7.8 million in 2023, then sank by 83.47% to $1.3 million in 2024, then surged by 283.97% to $5.0 million in 2025, then plunged by 61.97% to $1.9 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.9 million (Q1 2026), $5.0 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.